S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal
S&P 500   4,267.52
DOW   33,665.02
QQQ   348.82
10 Best Airline Stocks to Buy
New "Mined in America" Lithium Opportunities? (Ad)
Stock market today: Wall Street listless early ahead of new labor market data
What is a Growth Stock Mutual Fund?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Ollie’s Bargain Outlet Goes On Sale 
Will MicroVision Maintain Its Momentum After the Short Squeeze?
Graphite Shortage Could Derail the $7 Trillion EV Transition (Ad)
Campbell Soup Company Leads Staples Stocks Into The Buy Zone
Apple Partnership Strengthens Unity Software's Investment Appeal

Invitae (NVTA) Stock Forecast, Price & News

$1.19
-0.05 (-4.03%)
(As of 06/7/2023 ET)
Compare
Today's Range
$1.18
$1.26
50-Day Range
$1.05
$1.63
52-Week Range
$1.02
$9.00
Volume
6.04 million shs
Average Volume
8.45 million shs
Market Capitalization
$310.20 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.88

Invitae MarketRank™ Forecast

Analyst Rating
Hold
1.55 Rating Score
Upside/​Downside
226.3% Upside
$3.88 Price Target
Short Interest
Bearish
18.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.15
Upright™ Environmental Score
News Sentiment
0.56mentions of Invitae in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$198,630 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.48) to ($1.14) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.06 out of 5 stars

Medical Sector

394th out of 981 stocks

Medical Laboratories Industry

10th out of 22 stocks


NVTA stock logo

About Invitae (NYSE:NVTA) Stock

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.

Receive NVTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Invitae and its competitors with MarketBeat's FREE daily newsletter.

NVTA Stock News Headlines

The Real Problem With "Made in America" Lithium
Politicians love to say they support "Made in America" when it comes to manufacturing. But when it comes to lithium - the metal fueling our transition to electric vehicles - it's not that simple.
Invitae Co. (NYSE:NVTA) CAO Sells $25,870.80 in Stock
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
Invitae Co. (NYSE:NVTA) CEO Sells $54,518.40 in Stock
StockNews.com Begins Coverage on Invitae (NYSE:NVTA)
Raymond James Downgrades Invitae (NYSE:NVTA) to Underperform
Invitae to Appeal Trial Verdict
Invitae (NVTA) Q1 2023 Earnings Call Transcript
Invitae (NVTA) to Release Quarterly Earnings on Tuesday
See More Headlines

NVTA Price History

NVTA Company Calendar

Last Earnings
5/09/2023
Today
6/08/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Fax
N/A
Employees
1,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.88
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+226.3%
Consensus Rating
Hold
Rating Score (0-4)
1.55
Research Coverage
11 Analysts

Profitability

Net Income
$-3,106,290,000.00
Net Margins
-611.14%
Pretax Margin
-613.29%

Debt

Sales & Book Value

Annual Sales
$516.30 million
Cash Flow
$9.15 per share
Book Value
$0.42 per share

Miscellaneous

Free Float
257,808,000
Market Cap
$310.20 million
Optionable
Optionable
Beta
1.75

Key Executives

  • Dr. Randal W. Scott Ph.D. (Age 65)
    Co-Founder & Chairman
    Comp: $50k
  • Mr. Kenneth D. Knight (Age 62)
    Pres, CEO & Director
    Comp: $1.4M
  • Ms. Yafei Wen (Age 50)
    Chief Financial Officer
    Comp: $1.4M
  • Mr. Thomas R. BridaMr. Thomas R. Brida (Age 52)
    Gen. Counsel, Chief Compliance Officer & Sec.
    Comp: $776.72k
  • Ms. Hoki Luk (Age 47)
    Head of Investor Relations and Capital Markets
  • Mr. Lee Bendekgey J.D. (Age 65)
    Chief Policy Officer
  • Ms. Shelly D. GuyerMs. Shelly D. Guyer (Age 63)
    Chief Sustainability Officer
  • Ms. Desarie French
    Chief Talent Officer
  • Dr. W. Michael Korn M.D.
    Chief Medical Officer
  • Mr. Jackson J. Finks C.F.A.
    CFA, Director of Investor Relations & Strategic Fin.













NVTA Stock - Frequently Asked Questions

Should I buy or sell Invitae stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Invitae in the last twelve months. There are currently 5 sell ratings and 6 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVTA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVTA, but not buy additional shares or sell existing shares.
View NVTA analyst ratings
or view top-rated stocks.

What is Invitae's stock price forecast for 2023?

11 Wall Street research analysts have issued twelve-month price objectives for Invitae's stock. Their NVTA share price forecasts range from $1.50 to $8.00. On average, they anticipate the company's share price to reach $3.88 in the next twelve months. This suggests a possible upside of 226.3% from the stock's current price.
View analysts price targets for NVTA
or view top-rated stocks among Wall Street analysts.

How have NVTA shares performed in 2023?

Invitae's stock was trading at $1.86 at the beginning of 2023. Since then, NVTA shares have decreased by 36.0% and is now trading at $1.19.
View the best growth stocks for 2023 here
.

When is Invitae's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our NVTA earnings forecast
.

How were Invitae's earnings last quarter?

Invitae Co. (NYSE:NVTA) released its quarterly earnings results on Tuesday, May, 9th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.41) by $0.04. The medical research company earned $117.36 million during the quarter, compared to analyst estimates of $116.57 million. Invitae had a negative net margin of 611.14% and a negative trailing twelve-month return on equity of 285.28%. The company's quarterly revenue was down 5.1% on a year-over-year basis. During the same period in the previous year, the company earned ($0.78) EPS.

What guidance has Invitae issued on next quarter's earnings?

Invitae updated its FY 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $500.00M-, compared to the consensus revenue estimate of $504.52 million.

What is Sean George's approval rating as Invitae's CEO?

59 employees have rated Invitae Chief Executive Officer Sean George on Glassdoor.com. Sean George has an approval rating of 87% among the company's employees.

What other stocks do shareholders of Invitae own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Invitae investors own include NVIDIA (NVDA), Block (SQ), Roku (ROKU), Tesla (TSLA), Alibaba Group (BABA), Trade Desk (TTD), Shopify (SHOP), Salesforce (CRM), Advanced Micro Devices (AMD) and Okta (OKTA).

When did Invitae IPO?

(NVTA) raised $76 million in an initial public offering (IPO) on Thursday, February 12th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan acted as the underwriter for the IPO and Cowen and Company and Leerink Partners were co-managers.

What is Invitae's stock symbol?

Invitae trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVTA."

Who are Invitae's major shareholders?

Invitae's stock is owned by many different retail and institutional investors. Top institutional investors include ARK Investment Management LLC (12.78%), BlackRock Inc. (8.45%), Sumitomo Mitsui Trust Holdings Inc. (6.92%), Nikko Asset Management Americas Inc. (6.92%), Baker BROS. Advisors LP (3.41%) and State Street Corp (3.17%). Insiders that own company stock include Artur Bergman, E Lee Bendekgey, Eric Aguiar, Geoffrey Crouse, Jason W Myers, Katherine Stueland, Kenneth D Knight, Robert F Werner, Robert F Werner, Robert L Nussbaum, Robert L Nussbaum, Sean E George, Sean E George, Shelly D Guyer, Thomas Brida and Yafei Wen.
View institutional ownership trends
.

How do I buy shares of Invitae?

Shares of NVTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Invitae's stock price today?

One share of NVTA stock can currently be purchased for approximately $1.19.

How much money does Invitae make?

Invitae (NYSE:NVTA) has a market capitalization of $310.20 million and generates $516.30 million in revenue each year. The medical research company earns $-3,106,290,000.00 in net income (profit) each year or ($13.32) on an earnings per share basis.

How many employees does Invitae have?

The company employs 1,700 workers across the globe.

How can I contact Invitae?

Invitae's mailing address is 1400 16th Street, SAN FRANCISCO CA, 94103. The official website for the company is www.invitae.com. The medical research company can be reached via phone at (628) 213-3369 or via email at ir@invitae.com.

This page (NYSE:NVTA) was last updated on 6/8/2023 by MarketBeat.com Staff

My Account -